Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 2Suspended 1Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Dermatologic 1

Conditions

Prostatic Neoplasms 26Carcinoma, Renal Cell 10Melanoma 4Urinary Bladder Neoplasms 3Neoplasms 3Neoplasm Metastasis 3Colorectal Neoplasms 3Breast Neoplasms 3Triple Negative Breast Neoplasms 2Pancreatic Neoplasms 2Kidney Neoplasms 2Colonic Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Testicular Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Radiation Injuries 1Prostatic Hyperplasia 1Penile Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Nocturia 1Nephrolithiasis, Calcium Oxalate 1Multiple Myeloma 1Metastatic Castration Resistant Prostate Cancer (mCRPC) 1Metastatic Castrate Resistant Prostate Cancer 1Mesothelioma 1

Interventions

imisopasem manganese 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Hypotension × Genitourinary × Clear all
NCT00033956 2005-06-24

Evaluation of M40403 for the Prevention of Dose Limiting Toxicities of High Dose IL-2

MetaPhore Pharmaceuticals

Phase 1/2 Suspended
48 enrolled
DermatologicGenitourinary

Carcinoma, Renal Cell, Hypotension, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡